Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BCAL Diagnostics Limited ( (AU:BDX) ) has provided an announcement.
BCAL Diagnostics director Jayne Shaw has increased her shareholding in the company through an on-market purchase of 300,000 ordinary shares on 16 March 2026, paying $29,251 for the stake. The transaction, made via entities she controls, lifts her total holdings across various accounts while maintaining her existing 2,000,000 options with a $0.25 exercise price expiring in October 2027.
The incremental investment signals continued confidence from a key board member in BCAL Diagnostics’ prospects and aligns her interests more closely with other shareholders. Such director buying activity is often watched by investors as an indicator of internal sentiment about future performance and strategic direction, particularly in early-stage or growth-focused medical diagnostics businesses.
The most recent analyst rating on (AU:BDX) stock is a Sell with a A$0.09 price target. To see the full list of analyst forecasts on BCAL Diagnostics Limited stock, see the AU:BDX Stock Forecast page.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited is an Australian medical diagnostics company developing and commercialising blood-based tests, with a focus on breast cancer detection. The company targets healthcare providers and diagnostic markets seeking less invasive, earlier-stage cancer screening and monitoring solutions.
Average Trading Volume: 273,712
Technical Sentiment Signal: Buy
Current Market Cap: A$36.87M
For an in-depth examination of BDX stock, go to TipRanks’ Overview page.